NN Investment Partners Holdings N.V. boosted its holdings in shares of Stryker Co. (NYSE:SYK) by 1.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,511 shares of the medical technology company’s stock after buying an additional 793 shares during the period. NN Investment Partners Holdings N.V.’s holdings in Stryker were worth $10,948,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of SYK. Nordea Investment Management AB raised its position in Stryker by 113.0% during the third quarter. Nordea Investment Management AB now owns 2,241,051 shares of the medical technology company’s stock valued at $603,739,000 after buying an additional 1,189,087 shares during the period. BlackRock Inc. boosted its stake in shares of Stryker by 4.5% during the 3rd quarter. BlackRock Inc. now owns 24,204,161 shares of the medical technology company’s stock worth $6,383,121,000 after acquiring an additional 1,035,957 shares in the last quarter. Amundi bought a new stake in shares of Stryker during the 2nd quarter worth about $115,861,000. Invesco Ltd. boosted its stake in shares of Stryker by 45.1% during the 2nd quarter. Invesco Ltd. now owns 1,321,046 shares of the medical technology company’s stock worth $343,116,000 after acquiring an additional 410,574 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Stryker by 54.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 819,507 shares of the medical technology company’s stock worth $212,851,000 after acquiring an additional 290,548 shares in the last quarter. 73.28% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Srikant M. Datar sold 1,000 shares of the firm’s stock in a transaction on Thursday, November 11th. The stock was sold at an average price of $263.12, for a total value of $263,120.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Glenn S. Boehnlein sold 2,778 shares of the firm’s stock in a transaction on Friday, December 10th. The stock was sold at an average price of $259.79, for a total value of $721,696.62. The disclosure for this sale can be found here. 6.70% of the stock is currently owned by company insiders.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Wednesday, October 27th. The medical technology company reported $2.20 EPS for the quarter, missing the Zacks’ consensus estimate of $2.28 by ($0.08). The firm had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $4.23 billion. Stryker had a net margin of 11.40% and a return on equity of 25.73%. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.14 earnings per share. On average, equities analysts expect that Stryker Co. will post 9.1 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 31st. Shareholders of record on Friday, December 31st will be given a $0.695 dividend. This represents a $2.78 dividend on an annualized basis and a yield of 1.04%. This is a positive change from Stryker’s previous quarterly dividend of $0.63. The ex-dividend date is Thursday, December 30th. Stryker’s dividend payout ratio (DPR) is presently 55.94%.
Several analysts have recently issued reports on the company. Zacks Investment Research downgraded Stryker from a “hold” rating to a “sell” rating and set a $286.00 price target for the company. in a research note on Tuesday, September 28th. Robert W. Baird restated a “buy” rating and set a $301.00 target price on shares of Stryker in a research note on Friday, October 29th. Morgan Stanley downgraded Stryker from an “overweight” rating to an “equal weight” rating and set a $305.00 target price for the company. in a research note on Friday, January 7th. They noted that the move was a valuation call. SVB Leerink restated an “outperform” rating on shares of Stryker in a research note on Friday, October 22nd. Finally, Royal Bank of Canada began coverage on Stryker in a report on Thursday, December 9th. They issued a “sector perform” rating and a $278.00 price target for the company. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $293.74.
Stryker Corp. engages in the provision of medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg, and Neurotechnology & Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The MedSurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling and reprocessed medical devices.
Further Reading: Producer Price Index (PPI)
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.